A recent study highlights a patient with type 1 diabetes achieving sustained insulin independence after stem cell transplantation. This marks a significant shift from symptom management to a potential one-time cure, repairing the body's ability to produce insulin and moving healthcare from treatment to repair.

Max Marchione consistently uses the success of GLP-1 agonists (e.g., Ozempic) to counter the claim that peptides are an inferior drug class. By highlighting that perhaps the most impactful drug of the modern era is a peptide, he argues that the entire category holds immense, untapped potential that cannot be dismissed.

Originally for diabetes, GLP-1s' broad positive effects on inflammation, heart, and brain function position them as the first mainstream drugs for human enhancement and longevity, moving beyond simple disease management.

While GLP-1 has been a known target for a long time, the recent explosion in peptide therapeutics was primarily enabled by solving the historical challenge of poor half-life and exposure. Achieving one- or two-week half-lives through techniques like fatty acid acylation was the critical technological unlock for the field.

The dominance of peptides for GLP-1 therapeutics isn't a failure of antibodies but a success for picking the right tool. Peptides have a natural advantage when the therapeutic strategy involves engineering a natural ligand, making them a better starting point for certain targets like GPCRs.

Peptides are clinically categorized by whether they have identified receptors. Compounds like GLP-1s have known receptors, leading to strong, predictable effects. Others, like BPC-157, lack a clear target, resulting in more diffuse, less understood mechanisms of action.

Instead of complex ex-vivo cell engineering, Zag Bio's antibody platform programs the body's own thymus to produce long-lived, antigen-specific regulatory T-cells. This approach simplifies the therapeutic process by turning the organ into a drug-producing factory.

Aphaia's approach to metabolic disorders isn't hormone replacement. They use a targeted glucose formulation to "wake up" dormant sensing cells in the lower small intestine. This restores the body's natural ability to produce hundreds of regulatory hormones, fixing the root cause rather than just treating symptoms with high-dose injections.

The therapy is designed to be long-lasting, leveraging T-regs that persist for decades. However, it is also re-dosable, which the company frames as a "feature, not a bug." This unique positioning blends the appeal of a cure with the practical flexibility of a long-term management option.